Hanger Inc

Hanger — Investor Presentation (December 2018)

30 slides from Hanger's investor presentation, Dec 4, 2018

  1. Slide 1: Cautionary Note Forward Looking Statements

    Cautionary Note Forward Looking Statements page 02 This presentation contains certain “forward-looking statements” relating to the Company. All statements, other than statements of historical fact included herein, are “forward looking statements.” These forward looking statements are often identifie

  2. Slide 2: Hanger At a Glance

    Hanger At a Glance page 03 Who We Are: Industry leader in orthotics and prosthetics (O&P) services $4.1 billion1 addressable O&P domestic U.S. market Pioneered prosthetic devices in 1861 Focus on custom devices By The Numbers (2017): Net Revenue $1.041 billion Adjusted EBITDA2 $120 million 4,600 emp

  3. Slide 3: Business Mix: Primary Focus on the Provision of Specialty Health Care

    Business Mix Primary Focus on the Provision of Specialty Health Care page 04 Patient Care $852.0 million 81.9% revenue Patient Care $148.0 million 17.4% margin G&A expense ($66.9) million Products & Services $188.8 million 18.1% revenue Products & Services $38.5 million 20.4% margin 2017 Hanger Net

  4. Slide 4: Investment Thesis: Industry Leader With Multiple Strategic Advantages

    Investment Thesis Industry Leader With Multiple Strategic Advantages page 05 The leading provider of orthotic and prosthetic services in the United States 1 $4.1 billion market for prescription prostheses, orthoses and prefabricated/off-the-shelf orthoses, and related services. Demand drivers are br

  5. Slide 5: Agenda: Discussion Points

    page 06 Our Market Focused Growth Strategy Patient Care Financial Performance Discussion Points Agenda Products & Services

  6. Slide 6: Agenda: Discussion Points

    page 07 Our Market Focused Growth Strategy Patient Care Financial Performance Discussion Points Agenda Products & Services

  7. Slide 7: Orthotics and Prosthetics (O&P)

    Orthotics and Prosthetics (O&P) Over 90% of Hanger’s revenue is related to O&P page 08 Prosthetic devices replace a missing limb or portion of a limb Provided to patients with amputated or congenitally absent limbs to replace the function and appearance of a limb Prosthetics are customized to meet t

  8. Slide 8: Agenda: Discussion Points

    page 09 Our Market Focused Growth Strategy Patient Care Financial Performance Discussion Points Agenda Products & Services

  9. Slide 9: Patient Care Differentiators

    Patient Care Differentiators Building Sustainable Advantages in a Fragmented Industry page 010 National network and market leadership Enhancing productivity and cost management through an enterprise supply chain Driving patient engagement, connectivity and satisfaction Optimizing reimbursement throu

  10. Slide 10: Scale as a Competitive Advantage

    Scale as a Competitive Advantage National Network Brings Hanger Closer to the Community page 011 1 1,500 Clinicians Hanger employs over 20% of the board certified, O&P clinicians in the U.S. Competitors are spread out in small local practitioner settings. 3 800 Patient Care Locations Hanger is the o

  11. Slide 11: Market Leader In a Fragmented Industry

    page 012 Market Leader In a Fragmented Industry O&P Patient Care Clinic Market (by location) Approximately 3,400 Clinics Hanger Clinic 15 next largest O&P providers ranging from 14 - 26 clinics Veterans Administration Rest of market 20% of O&P clinics in the nation Hanger currently operates 786 pati

  12. Slide 12: Agenda: Discussion Points

    page 013 Our Market Focused Growth Strategy Patient Care Financial Performance Discussion Points Agenda Products & Services

  13. Slide 13: Products and Services: National Scale Supports Profitable Growth

    Products and Services National Scale Supports Profitable Growth page 014 68% of products & services net revenue derived from the distribution of O&P components and related devices through “SPS” Provides comprehensive catalog to independent O&P providers nationwide A one-stop destination O&P industry

  14. Slide 14: Agenda: Discussion Points

    page 015 Our Market Focused Growth Strategy Patient Care Financial Performance Discussion Points Agenda Products & Services

  15. Slide 15: Growth Strategy: Build a Durable and Scalable Platform

    Growth Strategy Build a Durable and Scalable Platform page 016 Accomplishments: Stabilize and Invest G&A investment – leadership, infrastructure, technology Complete restatement of financials (May 2017) Listed on NYSE (September 2018) Operational initiatives Centralized revenue cycle management (RCM

  16. Slide 16: Growth Strategy: Accelerate to Growth

    page 017 Drive organic revenue growth via market share Drive to exceed industry growth rate of 1.5 - 2.0% Add clinicians Drive higher throughput and productivity Higher volume through referrals Focus on high-value customized devices Growth Strategy Accelerate to Growth 2019 - 2020 2020-Beyond 2015 -

  17. Slide 17: Agenda: Discussion Points

    page 018 Our Market Focused Growth Strategy Patient Care Financial Performance Discussion Points Agenda Products & Services

  18. Slide 18: Historical Performance: Annual and Recent Quarter Net Revenue

    Historical Performance Annual and Recent Quarter Net Revenue page 019 Implemented claims documentation initiatives in 2016 to improve long-term revenue quality Revenue growth in both business segments in the second and third quarters of 2018 Third Quarter $258.0 $262.9 2017 2018 $1,012.1 $1,067.2 $1

  19. Slide 19: Historical Performance: Annual and Recent Quarter Adjusted EBITDA

    Historical Performance Annual and Recent Quarter Adjusted EBITDA1 page 020 2017 Adjusted EBITDA improvement resulted primarily from lower disallowed revenue, personnel expenses and operating expenses in the Patient Care segment Products and Services segment declined on lower revenue from therapeutic

  20. Slide 20: Transformation Yields Results: Same Clinic Revenue Per Day

    Transformation Yields Results Annual and Quarterly Same Clinic Revenue Per Day page 021 Annual % change1 Revenue impacted by claims documentation initiative Quarterly % change1 Since its re-engineering of processes in 2016, Hanger has re-established consistent same clinic growth Q3 2018 same clinic

  21. Slide 21: Payor Mix and Accounts Receivables Trend

    page 022 Payor Mix and Accounts Receivables Trend Multi-Year Improvements in Working Capital Conversion Accounts Receivable, net (Orange Bars) $ thousands Day Sales Outstanding (Black Line) Diverse reimbursement mix combined with improved A/R aging has driven stronger working capital characteristics

  22. Slide 22: Leverage: Favorable Deleveraging Trend

    page 023 Leverage Favorable Deleveraging Trend Indebtedness Leverage Ratio As of September 30, 2018 3.4 3.6 3.8 4.0 4.2 4.4 4.6 $425.0 $450.0 $475.0 $500.0 $525.0 2014 2015 2016 2017 2018 Q3 Net Debt Leverage Ratio 2018 1 Revolver - $ Term B Loan, Due 2024 (L+350) 502.5 Seller Notes 3.8 Financial Le

  23. Slide 23: Other Considerations: Use Excess Cash Flow to Execute Growth Strategy

    Other Considerations Use Excess Cash Flow to Execute Growth Strategy page 024 $344.2 million, or 66%, of debt hedged or otherwise bearing fixed rate Current rate of approximately $33 million in annualized cash interest expense, or 6.3% Flexible Balance Sheet2 Q3 2018 TTM Free Cash Flow (Adjusted EBI

  24. Slide 24: 2018 Outlook Generally Consistent with 2017

    2018 Outlook Generally Consistent with 2017 page 025 For the full year 2018, Hanger anticipates net revenue and Adjusted EBITDA to be generally consistent with actual 2017 results Net Income and Adjusted Net Earnings1 Hanger anticipates net income and adjusted net earnings on a total and per share b

  25. Slide 25: Investment Thesis: Industry Leader With Multiple Strategic Advantages

    Investment Thesis Industry Leader With Multiple Strategic Advantages page 026 The leading provider of orthotic and prosthetic services in the United States 1 $4.1 billion market for prescription prostheses, orthoses and prefabricated/off-the-shelf orthoses, and related services. Demand drivers are b

  26. Slide 26: Appendix: Non-GAAP Reconciliations

    Appendix Non-GAAP Reconciliations

  27. Slide 27: Non-GAAP Reconciliations: Net Income to Segment Adjusted EBITDA

    Non-GAAP Reconciliations Net Income to Segment, Adjusted EBITDA and Adjusted EBITDA Margin as a Percentage of Net Revenue 2017 page 029 For the Year Ended December 31, 2017 Patient Care Net income (loss) - as reported (GAAP) 90,350 Adjustments to calculate EBITDA: Depreciation and amortization 21,36

  28. Slide 28: Non-GAAP Reconciliations: Net Income to Adjusted EBITDA Third Quarter and YTD

    Non-GAAP Reconciliations Net Income to Adjusted EBITDA Third Quarter and YTD 2018 v. 2017 page 030

  29. Slide 29: Non-GAAP Reconciliations: Net Income to Adjusted EBITDA TTM September 30, 2018

    Non-GAAP Reconciliations Net Income to Adjusted EBITDA TTM September 30, 2018 page 031 For the Trailing Twelve Months Ended September 30, 2018 Net income (loss) - as reported (GAAP) (89,734) $ Adjustments to calculate EBITDA: Depreciation and amortization 37,217 Interest expense, net 43,008 Loss on

  30. Slide 30: Non-GAAP Reconciliations

    Non-GAAP Reconciliations Net Income to Adjusted EBITDA TTM September 30, 2018 For the Trailing Twelve Months Ended September 30, 2018 Net income (loss) - as reported (GAAP) $ (89,734) Adjustments to calculate EBITDA: Depreciation and amortization 37,217 Interest expense, net 43,008 Loss on extinguis

Hanger — Investor Presentation (December 2018) on 6ix